GlassScriptPhysician profile
Ivette S Vigoda
NPI 1467724286
$10,135.31
in general payments reported to CMS, 2019-2025
45 companies · $3,334 in 2025
The $3,334 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $397 · 2021: $246 · 2022: $646 · 2023: $2,085 · 2024: $2,751 · 2025: $3,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,894 · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,893.58 |
| Education | $276.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,249.40 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Novartis Pharmaceuticals Corporation | $1,209.80 | 2019-2025 | |
| Pfizer INC. | $1,027.22 | 2019-2025 | |
| Daiichi Sankyo INC. | $589.31 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Merck Sharp & Dohme LLC | $582.17 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $524.16 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $466.26 | 2019-2025 | Pomalyst, Opdivo, Krazati |
| Genzyme Corporation | $461.08 | 2019-2025 | |
| Gilead Sciences, INC. | $425.92 | 2022-2025 | Trodelvy |
| Incyte Corporation | $229.62 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Glaxosmithkline, LLC. | $216.90 | 2025 | Jemperli, Ojjaara |
| Stemline Therapeutics INC. | $213.94 | 2024-2025 | Orserdu |
| Eisai INC. | $213.43 | 2023-2025 | |
| Celgene Corporation | $206.34 | 2021-2025 | Pomalyst, Reblozyl |
| Seagen INC. | $205.80 | 2019-2025 | Adcetris, Padcev |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $204.48 | 2023-2024 | Monoferric, Cosela |
| Taiho Oncology, INC. | $167.70 | 2023-2025 | |
| Emd Serono, INC. | $165.05 | 2022-2024 | Bavencio |
| Rigel Pharmaceuticals, INC. | $162.85 | 2019-2024 | Rezlidhia, Tavalisse |
| Amgen INC. | $155.65 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $155.31 | 2023-2025 | Libtayo |
| Grifols USA, LLC | $146.14 | 2024-2025 | Gamunex-C |
| Abbvie INC. | $134.76 | 2024-2025 | |
| Astellas Pharma US INC | $125.65 | 2023-2025 | Vyloy, Padcev, Xtandi |
| Jazz Pharmaceuticals INC. | $122.56 | 2023-2025 | |
| Genmab U.S., INC. | $109.28 | 2023-2024 | Tivdak |
| Lilly USA, LLC | $100.35 | 2019-2025 | Verzenio, Jaypirca |
| Alexion Pharmaceuticals, INC. | $51.09 | 2019-2024 | Ultomiris |
| Sumitomo Pharma America, INC. | $50.29 | 2023 | Orgovyx |
| Adaptive Biotechnologies Corporation | $49.59 | 2023-2024 | Clonoseq |
| Bayer Healthcare Pharmaceuticals INC. | $45.60 | 2019-2024 | |
| Myriad Genetic Laboratories, INC. | $45.44 | 2023-2024 | Precisetumor |
| Sobi, INC | $42.94 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.70 | 2022-2023 | Gilotrif |
| Azurity Pharmaceuticals, INC. | $35.90 | 2025 | Danziten |
| Foundation Medicine, INC. | $27.34 | 2023 | |
| Acceleron Pharma, INC. | $24.50 | 2020 | |
| Puma Biotechnology, INC. | $23.27 | 2023 | Nerlynx |
| Genentech USA, INC. | $23.10 | 2019 | |
| Kyowa Kirin, INC. | $22.98 | 2023 | Poteligeo |
| Global Blood Therapeutics, INC. | $20.01 | 2022 | |
| Morphosys, US INC. | $19.34 | 2023 | Monjuvi |
| Dova Pharmaceuticals | $18.75 | 2020 | |
| Tactile Systems Technology INC | $15.01 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivette Vigoda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.